Vivos Therapeutics, Inc. SEC filings VVOS
Vivos Therapeutics, Inc. has 301 filings in SEC EDGAR's recent list, going back to Sep 28, 2017. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 21, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| PRER14A | Filing | Oct 21, 2026 | — |
| NT 10-Q | Filing | May 15, 2026 | Mar 31, 2026 |
| EFFECT | Filing | May 8, 2026 | — |
| CORRESP | Letter to the SEC | May 6, 2026 | — |
| NT 10-K | Filing | Mar 31, 2026 | Dec 31, 2025 |
| UPLOAD | Letter from the SEC | Feb 23, 2026 | — |
| EFFECT | Filing | Jan 7, 2026 | — |
| NT 10-Q | Filing | Nov 14, 2025 | Sep 30, 2025 |
| EFFECT | Filing | Sep 10, 2025 | — |
| CORRESP | Letter to the SEC | Sep 8, 2025 | — |
| NT 10-Q | Filing | Aug 14, 2025 | Jun 30, 2025 |
| UPLOAD | Letter from the SEC | Feb 13, 2025 | — |
| EFFECT | Filing | Jan 30, 2025 | — |
| CORRESP | Letter to the SEC | Jan 29, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2025 | — |
| EFFECT | Filing | Aug 7, 2024 | — |
| CORRESP | Letter to the SEC | Aug 5, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 2, 2024 | — |
| EFFECT | Filing | Apr 26, 2024 | — |
| CORRESP | Letter to the SEC | Apr 24, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 12, 2024 | — |
| EFFECT | Filing | Dec 1, 2023 | — |
| CORRESP | Letter to the SEC | Nov 30, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 30, 2023 | — |
| NT 10-Q | Filing | Aug 15, 2023 | Jun 30, 2023 |
| NT 10-Q | Filing | May 15, 2023 | Mar 31, 2023 |
| EFFECT | Filing | Feb 8, 2023 | — |
| CORRESP | Letter to the SEC | Feb 6, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2023 | — |
| NT 10-Q | Filing | Aug 15, 2022 | Jun 30, 2022 |
| EFFECT | Filing | Feb 14, 2022 | — |
| CORRESP | Letter to the SEC | Feb 14, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 14, 2022 | — |
| EFFECT | Filing | May 19, 2021 | — |
| CORRESP | Letter to the SEC | May 18, 2021 | — |
| EFFECT | Filing | May 6, 2021 | — |
| UPLOAD | Letter from the SEC | May 4, 2021 | — |
| CORRESP | Letter to the SEC | May 4, 2021 | — |
| CORRESP | Letter to the SEC | May 4, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 20, 2021 | — |
| DRS | Filing | Apr 13, 2021 | — |
| EFFECT | Filing | Dec 10, 2020 | — |
| CERT | Filing | Dec 10, 2020 | — |
| 8-A12B | Filing | Dec 10, 2020 | — |
| CORRESP | Letter to the SEC | Dec 9, 2020 | — |
| CORRESP | Letter to the SEC | Dec 9, 2020 | — |
| CORRESP | Letter to the SEC | Nov 25, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 24, 2020 | — |
| CORRESP | Letter to the SEC | Oct 26, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 16, 2020 | — |
| CORRESP | Letter to the SEC | Oct 9, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 25, 2020 | — |
| DRS | Filing | Aug 31, 2020 | — |
| D | Filing | Feb 20, 2020 | — |
| D | Filing | May 16, 2019 | — |
| D/A | Filing | Sep 29, 2017 | — |
| D | Filing | Sep 28, 2017 | — |
Showing 57 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- VVOS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Littleton, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1716166
- Former names
- Vivos BioTechnologies, Inc. (until Sep 29, 2017)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.